Value proposition

Accelerating biomedical research by connecting biopharmas with the right preclinical cancer models and CRO partners

Repositive is committed to accelerating the development of precision cancer therapies to the clinic by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of pre-clinical cancer research.

Through its Cancer Models Scout service, Repositive is helping biopharmas to optimise their pre-clinical cancer projects by identifying the most suitable cancer models for their requirements from its world-leading database of over 8000 models, as well as via outreach to an extended network of CRO contacts.

Repositive works to connect researchers with the right CRO partners who have first-class expertise and years of experience in running similar studies, to ensure biopharmas receive the best advice for planning and conducting their oncology projects.

Download our latest eBook on AI in drug discovery here: https://mailchi.mp/repositive.io/c1tpoe6oke

cancer models, preclinical research, drug development, translational oncology, genomic data, biotech, and pharma